Skip to main content

Table 1 Clinicopathologic features of breast secretory carcinomas

From: Clinicopathological features and genomic profiles of a group of secretory breast carcinomas in which progressive cases have more complex genomic features

Patient

Sex

Age

Position

Associated in situ

carcinoma

Tumor size

(cm)

Lymph node

metastasis

Pathological stage

ER

PR

HER2

Ki-67

S-100

Pan-TRK

Treatment

Follow-up (month)

1

Female

39

Left

No

1.0

0

T1N0M0

Weak positive

negative

negative

5%

positive

positive

mastectomy, LND, CT

140m contralateral SBC

 

Female

51

Right

No

1.1

0

T1N0M0

Weak positive

negative

negative

5%

positive

positive

mastectomy, LND, CT

30m ANED

2

Female

42

Right

Yes

4.0

2

T2N1M0

negative

negative

negative

30%

positive

positive

mastectomy, LND, CT

84m recurrence and distant metastasis

 

Female

49

Chest wall

No

2.5

NA

-

negative

negative

negative

35%

positive

positive

L,CT,RT,

5m ANED

3

Female

41

Right

No

2.0

0

T1N0M0

moderate to strong positive

negative

negative

15%

positive

positive

L, LND, CT,RT, HT

18m ANED

4

Female

33

Left

No

7.0

0

T2N0M0

negative

negative

negative

10%

positive

positive

L, LND

10m ANED

5

Female

39

Left

No

0.9

0

T1N0M0

negative

negative

negative

20%

positive

positive

mastectomy, LND,

8m ANED

  1. NA Not available, CT Chemotherapy, RT Radiotherapy, HT Hormonotherapy, ANED Alive with no evidence of disease, ER Estrogen receptor, PR Progestogen receptor, HER2 Human epidermal growth factor 2, LND Lymph node dissection, L Lumpectomy, m Month, T Tumor size, N Regional lymph node, M Distant metastasis